The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially in Western countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.
Ivabradine, heart failure and chronic kidney disease / Luca Di, Lullo1; Antonio, Bellasi2; Russo, Domenico; Mario, Cozzolino4; Claudio, Ronco5; Alberto, Santoboni1; Giovanni, Barbera1. - In: Nephrology @ Point of Care. - 1:(2015), pp. 39-43. [10.5301/poc.5000190]
Ivabradine, heart failure and chronic kidney disease
RUSSO, DOMENICO;
2015
Abstract
The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially in Western countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
